Mazzoni Center has joined with several other healthcare providers and LGBT organizations around the U.S. in calling on manufacturers of injectable estrogen to address the serious shortage that has been affecting trans women for the past several months. This shortage is affecting the availability of Delestrogen and its generic counterpart estradiol valerate in 40 mg/mL dosages, which is the preferred regimen for many transgender women.
Spokespersons for the companies that produce these injectable forms of estrogren have said that there is a manufacturing
Read more...